

## Cynata Receives Decision to Grant a Patent in Japan

**Melbourne, Australia; 27 January 2022:** Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has today announced that a Decision to Grant a Patent has been received from the Japanese Patent Office (JPO) for a patent application covering its proprietary Cymerus™ mesenchymal stem cell technology. The patent application entitled “Pluripotent Stem Cell Assay” is wholly-owned by Cynata.

The Decision to Grant a Patent is sent to the applicant (Cynata) when the JPO intends to issue a patent. This patent joins a rapidly growing estate of issued patents covering the Cymerus technology and builds on the broad IP protection of Cynata’s Cymerus™ manufacturing platform and its unique ability to yield highly consistent mesenchymal stem cells (MSCs) at scale, from a single donation, to create therapeutic stem cell products.

**Dr Ross Macdonald, Cynata’s Chief Executive Officer, said:**

*“This further patent, which is wholly-owned by Cynata, describes an important analytical procedure to assure the quality and uniformity of Cynata’s Cymerus MSC products. It builds on our already comprehensive patent portfolio to protect our unique and proprietary IP. Of particular relevance is the fact that this achievement is in Japan, the second largest market for pharmaceutical products and the leading country in regenerative medicine. The Cymerus platform enables manufacture of consistent, high-quality mesenchymal stem cells at scale. This unique and valuable characteristic of Cynata’s technology is key to the development of off-the-shelf therapeutic stem cell products to target a range of devastating diseases worldwide”.*

Cynata anticipates that the patent will be granted around early-March 2022, with an expiration date of 15 November 2037.

The inventors named on the patent are Professor Igor Slukvin, founder, advisor and shareholder of Cynata, Ms Diana Drier and Dr Derek Hei.

-ENDS-

Authorised for release by Dr Ross Macdonald, Managing Director & CEO

**CONTACTS:** Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, [ross.macdonald@cynata.com](mailto:ross.macdonald@cynata.com)  
Lauren Nowak, Media Contact, +61 (0)400 434 299, [laurenmaree@live.com.au](mailto:laurenmaree@live.com.au)

**About Cynata Therapeutics (ASX: CYP)**

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Planning for a Phase 2 clinical trial in GvHD is presently underway. Clinical trials of Cymerus products in osteoarthritis (Phase 3), respiratory failure and diabetic foot ulcers (DFU) are currently ongoing. In addition, Cynata has demonstrated utility of its Cymerus technology in



preclinical models of numerous diseases, including the clinical targets mentioned above, as well as critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

**Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.**